Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 60, Issue 8, 2013, Pages

  Yamada, Kayo ^a   Yasui, Masahiro ^a   Kondo, Osamu ^a   Sato, Maho ^a   Sawada, Akihisa ^a   Kawa, Keisei ^a   Inoue, Masami ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Imatinib mesylate; Ph+ALL; Reduced intensity conditioning

Indexed keywords

ETOPOSIDE; FLUDARABINE; IMATINIB; MELPHALAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TOXICITY; CHILD; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; FEASIBILITY STUDY; FEMALE; GROWTH RETARDATION; HUMAN; INDUCTION CHEMOTHERAPY; MALE; NAUSEA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REMISSION; SCHOOL CHILD; TOXICITY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84879246536     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24507     Document Type: Article

References (20)

1. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342:998-1006.
2. Aricò M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010; 28:4755-4761.
3. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2006; 108:1469-1477.
4. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105:3449-3457.
5. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol 2009; 27:5175-5181.
6. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol 2012; 13:936-945.
7. Rives S, Estella J, Gómez P, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): Results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011; 154:600-611.
8. Shimizu M, Sawada A, Yamada K, et al. Encouraging results of preserving ovarian function after allo-HSCT with RIC. Bone Marrow Transplant 2012; 47:141-142.
9. Sawada A, Sakata N, Kishimoto T, et al. Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia. Leuk Res 2009; 33:1710-1713.
10. Suzuki N, Yumura-Yagi K, Yoshida M, et al. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol. Pediatr Blood Cancer 2010; 54:71-78.
11. Yamada K, Yasui M, Sawada A, et al. Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. Pediatr Blood Cancer 2012; 58:300-302.
12. Schultz KR, Prestidge T, Camitta B. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: New and emerging treatment options. Expert Rev Hematol 2010; 3:731-742.
13. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18:348-371.
14. Satwani P, Morris E, Bradley MB, et al. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 2008; 50:1-8.
15. Inoue M, Okamura T, Yasui M, et al. Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children. Bone Marrow Transplant 2006; 37:601-605.
16. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85:387-398.
17. Larmonier N, Janikashvili N, LaCasse CJ, et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol 2008; 181:6955-6963.
18. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009; 89:251-252.
19. Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112:1005-1012.
20. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27:469-471.